New pneumonia vaccine shows promise in early trial for kids

NCT ID NCT06183216

Completed ⭐️ VACCINE ⭐️ Sponsor: Sinovac Research and Development Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1b trial tested a new 13-valent pneumococcal conjugate vaccine (PCV13) in 140 healthy infants (2 months old) and children (2-5 years). The goal was to check safety and immune response compared to an existing vaccine. Researchers monitored side effects and antibody levels to see if the new vaccine could protect against pneumococcal diseases like pneumonia and meningitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13)
What this could lead to: If successful, this could lead to a new vaccine option to protect children against pneumococcal infections like pneumonia and meningitis.
What could go wrong: This is an early phase 1 trial with only 140 participants, so results may not confirm broad effectiveness or safety. The vaccine may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Locations

Binchuan County Center for Diseases Control and Prevention

Dali, Yunnan, 671600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.